Locations
San Francisco, CA, USA · San Diego, CA, USA · California City, CA, USA
industry
Biotechnology
Size
51-200 employees
Stage
Series C+
founded in
2015
Turnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (SELECTED TIL) therapy. Turnstone’s novel TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as SELECTED TIL, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer, and colorectal cancer, and the company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next SELECTED TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit www.turnstonebio.com.
Something looks off?